RESEARCH MONOGRAPH · KDC-MN-293
Pramlintide
Pramlintide (Symlin) is a synthetic version of amylin, a peptide that the pancreatic beta cells release alongside insulin. Native amylin forms amyloid fibrils (not useful as a drug), so the synthetic version substitutes proline at three positions to keep it in solution. Approved in 2005 as an injection given before meals alongside insulin in type 1 and type 2 diabetes. Three effects: it slows stomach emptying (so glucose absorption is gradual), suppresses post-meal glucagon (which would otherwise raise blood sugar), and increases satiety. The combination smooths post-meal glucose peaks and modestly reduces insulin requirements and weight. Niche in clinical practice owing to the need for a separate injection. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Synthetic amylin analog
A synthetic analog of the pancreatic peptide hormone amylin; used adjunctively with insulin in type 1 and type 2 diabetes for postprandial glucose control.
Abstract
Pramlintide (modified 37-amino-acid amide derived from amylin; CAS 151126-32-8; molecular weight 3949.4) is a synthetic analog of amylin (islet amyloid polypeptide), a pancreatic beta-cell peptide co-secreted with insulin. The native amylin is amyloidogenic; pramlintide substitutes proline for residues at positions 25, 28, and 29 to disrupt amyloid fibril formation while preserving receptor binding. Approved by the FDA in 2005 under the trade name Symlin. Mechanism: amylin receptor agonism produces three principal effects: slowed gastric emptying (delays glucose absorption), suppression of postprandial glucagon (reduces hepatic glucose output), and increased satiety (promotes voluntary caloric reduction). Approved as adjunct to mealtime insulin in type 1 and insulin-using type 2 diabetes; produces approximately 0.4 percent reduction in HbA1c and modest weight loss. Plasma half-life is approximately 50 minutes; subcutaneous administration before each major meal. Used as the canonical amylin analog in metabolic research.
Mechanism of action
Amylin receptor agonist (calcitonin/CGRP-related receptor family); slows gastric emptying, suppresses postprandial glucagon, increases satiety.
Reported research dose ranges
Clinical 15 to 120 mcg subcutaneous before each major meal. Rodent studies 1 to 100 mcg/kg.
References
- Riddle MC, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009.
- Edelman SV, et al. Pramlintide as an adjunct treatment for type 2 diabetes. Endocr Pract 2007.
- Younk LM, et al. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother 2011.
Read the full monograph
The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.